Literature DB >> 29607130

Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer.

Andrew Song1, Bo Lu1.   

Abstract

Entities:  

Year:  2018        PMID： 29607130      PMCID： PMC5864629          DOI： 10.21037/jtd.2018.01.22

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

1.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

2.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Authors:  Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

Review 3.  Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.

Authors:  Timothy A Yap; Aislinn Macklin-Doherty; Sanjay Popat
Journal:  Eur J Cancer       Date:  2016-11-17       Impact factor: 9.162

4.  Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.

Authors:  Joseph K Salama; Michael D Hasselle; Steven J Chmura; Renuka Malik; Neil Mehta; Kamil M Yenice; Victoria M Villaflor; Walter M Stadler; Philip C Hoffman; Ezra E W Cohen; Philip P Connell; Daniel J Haraf; Everett E Vokes; Samuel Hellman; Ralph R Weichselbaum
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

Review 5.  Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.

Authors:  Stephanie G C Kroeze; Corinna Fritz; Morten Hoyer; Simon S Lo; Umberto Ricardi; Arjun Sahgal; Rolf Stahel; Roger Stupp; Matthias Guckenberger
Journal:  Cancer Treat Rev       Date:  2016-12-19       Impact factor: 12.111

6.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

Review 7.  An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

Authors:  Allison B Ashworth; Suresh Senan; David A Palma; Marc Riquet; Yong Chan Ahn; Umberto Ricardi; Maria T Congedo; Daniel R Gomez; Gavin M Wright; Giulio Melloni; Michael T Milano; Claudio V Sole; Tommaso M De Pas; Dennis L Carter; Andrew J Warner; George B Rodrigues
Journal:  Clin Lung Cancer       Date:  2014-05-15       Impact factor: 4.785

8.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

9.  Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

Authors:  C Zhou; Y L Wu; G Chen; J Feng; X-Q Liu; C Wang; S Zhang; J Wang; S Zhou; S Ren; S Lu; L Zhang; C Hu; C Hu; Y Luo; L Chen; M Ye; J Huang; X Zhi; Y Zhang; Q Xiu; J Ma; L Zhang; C You
Journal:  Ann Oncol       Date:  2015-07-03       Impact factor: 32.976

10.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316
View more
  2 in total

1.  Lung-molGPA Index Predicts Survival Outcomes of Non-Small-Cell Lung Cancer Patients with Synchronous or Metachronous Brain Metastases.

Authors:  Kaiyan Chen; Fanrong Zhang; Yun Fan; Guoping Cheng
Journal:  Onco Targets Ther       Date:  2020-09-04       Impact factor: 4.147

2.  Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience.

Authors:  Guangjin Chai; Yutian Yin; Xiaoying Zhou; Qilong Hu; Bo Lv; Zhaohui Li; Mei Shi; Lina Zhao
Journal:  Transl Lung Cancer Res       Date:  2020-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.